Search documents
RH Reports Tariff, Weather Impacts in Fourth Quarter, Projects First-Quarter Revenue Decline
WSJ· 2026-03-31 21:05
The home-furnishings company expects revenue to fall between 2% and 4% in the current first quarter. ...
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
Globenewswire· 2026-03-31 21:05
On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-in- kind interleukin-2 ("IL-2") fusion immunotherapeutic. IL-2, the active component of HCW9302, is the cytokine in humans and other vertebrates responsible for maintaining the proper numbers and functio ...
American Home Shield and Rachel Dratch Return for Year Three of “Warrantina” to Demystify the Misconceptions of Home Warranties
Businesswire· 2026-03-31 21:05
MEMPHIS, Tenn.--(BUSINESS WIRE)--Frontdoor, Inc. (NASDAQ: FTDR), the parent company of American Home Shield, the nation's leading provider of home warranties, today announced the third year of its "Don't Worry. Be Warranty.†marketing campaign. The latest iteration reunites American Home Shield with Emmy®-nominated comedienne Rachel Dratch – bringing back her well-known "Warrantina†character to further educate homeowners and demystify the home warranty category. Entering its third year, the ca. ...
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Globenewswire· 2026-03-31 21:05
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with ...
femasys(FEMY) - 2025 Q4 - Annual Report
2026-03-31 21:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | | 11-3713499 | | --- | --- | --- | | (State o ...
New Jersey American Water Concludes Temporary Treatment Change in Water Treatment Plants Serving Coastal Part of the State
Prnewswire· 2026-03-31 21:04
<!doctype html> <!-- For structured data --> <!-- For language declaration --> New Jersey American Water Concludes Temporary Treatment Change in Water Treatment Plants Serving Coastal Part of the State <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationCAMDEN, N.J., March 31, 2026 /PRNewswire/ -- On the week of April 13, New Jersey American Waterwill complete its scheduled routine treatment change and resume using chloramines at its Swimming River Water Treatment Plant in Colts N ...
Binah Capital Group, Inc.(BCG) - 2025 Q4 - Annual Results
2026-03-31 21:03
Exhibit 99.1 BINAH CAPITAL GROUP REPORTS RESULTS FOR FOURTH QUARTER AND FULL YEAR 2025 - Grew Total Revenue 11% Year-over-Year to $187.1 Million - - Assets Under Management ("AuM") Increased 11% Year-over-Year to $29.9 Billion - "We completed our first full year as a public company with strong results in the fourth quarter, which reflects the continuing growth of our differentiated platform," stated Craig Gould, Chief Executive Officer of Binah Capital Group. "The momentum we have created through our growth ...
KBR: Low Valuation And Healthy Long-Term Drivers Make It A Buy (NYSE:KBR)
Seeking Alpha· 2026-03-31 21:03
KBR ( KBR ) is trading at a significant discount versus historical levels. Its current forward P/E is over 40% lower than the 5-year historical average. While there are near-term headwinds due to the winding downWe focus on GARP (Growth at reasonable Price) opportunities in industrial, consumer, and technology sectors. We are among the top 50 financial experts (Out of ~39,000 tracked) as measured by Tipranks based on the consistency of our stock recommendations and returns generated https://www.tipranks.com ...
Nike's results were better than expected, but investors still aren't sold on its turnaround
MarketWatch· 2026-03-31 21:03
Nike reported quarterly results that were a bit better than Wall Street's expectations, but investors still didn't appear convinced of the sneaker giant's turnaround efforts. ...
Kodiak(KOD) - 2025 Q4 - Annual Report
2026-03-31 21:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State or other jurisd ...
